PATENT CLAIM ANALYSIS

Application Number: 15918195
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "210210"]

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

Claim (Index 14):
A method of treating a thromboembolic or an inflammatory disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of  claim 1  or a pharmaceutically acceptable salt or solvate form thereof.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 90.0
- Lexical Diversity: 1.17949
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14117513', '15361589', '14617979', '14886415', '14350411']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8342031897833895
- 35 USC 102 Novelty (BERT): 0.6334206684862469
- Combined Prediction Score: 0.8141249376536752
- Mean Citation Score: 542.883702
- Max Citation Score: 635.02765
- Similarity Product: 546.5720905609428

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test